Surrey Heartlands

Joint Formulary & PAD

Semaglutide - Prevention of cardiovascular events

You are here : Home > Formulary Search > Semaglutide - Prevention of cardiovascular events

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

This drug has not yet been assessed for formulary status for the prevention of cardiovascular events. Contact your pharmacy team for advice on making an application to APC.

This drug has not yet been assessed for formulary status for the prevention of cardiovascular events.

It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE have not yet carried out an appraisal but, once published, it will be considered by the APC within 90 days.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Semaglutide
Indication :
Prevention of cardiovascular events
Group Name :
Keywords :
Brand Names Include :
Wegovy
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Semaglutide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Prevention of cardiovascular events.

  • No records returned.

Committee Recommendations (0)

  • No records returned.